KalVista Pharmaceuticals (NASDAQ:KALV) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) in a report issued on Friday morning, Benzinga reports. They currently have a $32.00 target price on the specialty pharmaceutical company’s stock. A number of other brokerages have also recently weighed in on KALV. Cantor Fitzgerald upgraded KalVista […]

Leave a Reply

Your email address will not be published.

Previous post Analysts Set Teradyne, Inc. (NASDAQ:TER) Price Target at $141.50
Next post Robbins: Hamas hell-bent on torture, destruction